Getinge Ab Class B · OMXSTO:GETI_B
Getinge Ab Class B — Carnegie Nordic Health Care Seminar 2009
19 slides from Getinge Ab Class B's conference presentation, Mar 26, 2009
Slide 1: Carnegie Nordic Health Care Seminar
GETINGE Carnegie Nordic Health Care Seminar 26 March, 2009
Slide 2: Getinge Group 2009
Getinge Group 2009 Revenue:* SEK 24 billion Associates: 12 800 Revenue by Business area Revenue by Division in * Estimated revenue 2009 Medical Systems GETINGE 2009-03
Slide 3: Revenue by category
Revenue by category Projected 2009 Group USA GETINGE 2009-03
Slide 4: Geographical breakdown 2009 projected
GEOGRAPHICAL BREAKDOWN 2009 PROJECTED North America Western Europe 33% 46% Emerging markets, RoW 21% GETINGE 2009-03
Slide 5: Strategic direction
Strategic direction GETINGE 2009-03
Slide 6: Market leadership, integrated solutions
Market leadership Integrated solutions h Sterilization no 1 Disinfection no 1 Integrated Infection Control Patient Handling no 1 solutions Hygiene Systems no 1 h Wound Care no 2 Integrated solutions IPC / DVT no 1 for health care ergonomics Surgical Tables no 1 h Surgical Lights no 1 Ceiling Pendant
Slide 7: Financial targets and how we reach them
Financial targets ● and how we reach them GETINGE 2009-03
Slide 8: Group Financial targets
Group Financial targets 15% year over year average growth of pre tax earnings Development of existing positions: 7–8% Acquisition of globally leading product lines: 7–8% To reach and maintain an EBITA-margin of 18-19 % (current structure) Cash flow generation to sustain an external growth rate of 10
Slide 9: We believe we can continue to outperform our market
We believe we can continue to outperform our market by approximately 2% in coming year Increased exposure to faster growing emerging markets Sales synergies from recent acquisitions: Huntleigh, Cardiac & Vascular surgery divisions and Datascope New product development has expanded our market potenti
Slide 10: We can continue to strengthen our operating margins by
We believe that we can continue to strengthen our operating margins by: Ongoing realization of cost synergies from recent and pending acquisitions. Declining integration costs. Improved cost position through supply chain enhancement Exposure to product segments with higher profitability Introduction
Slide 11: Integration of recent acquisitions
Integration of recent acquisitions GETINGE 2009-03
Slide 12: Huntleigh integration
HUNTELIGH INTEGRATION Structural integration of Huntleigh is completed and cost synergies will exceed targeted 300 MSEK p.a. Additional cost synergies in 2009-2010 Improved logistics 3 PL Common IT infrastructure/administrative efficiencies Ongoing component localization in Poland/China Merger of sa
Slide 13: Integration of the Boston Scientific cardiac and vascular surgery divisions
INTEGRATION OF THE BOSTON SCIENTIFIC CARDIAC AND VASCULAR SURGERY DIVISIONS Actions in place to generate planned revenue synergies from 2009 onward (10% organic) Sales of revascularization products through Medical Systems existing sales channels on the OUS markets Sales of Medical Systems perfusion
Slide 14: Integration of Datascope Corp. USA
Integration of Datascope Corp. USA We expect revenue synergies from geographical and product complementarities to deliver organic top line growth of 10 % or better from 2010 onwards Elimination of duplication of sales infrastructure in 9 markets in North America, Europe and Asia Overlapping HQ struc
Slide 15: Financials
GETINGE Financials GETINGE 2009-03
Slide 16: Cash flow (MSEK) cont
Cash flow (MSEK) cont Operating cash flow before restructuring 3500 +20% 3 064 +19% 3000 +16% 2 554 2500 +12% 2 139 2000 1842 1644 1500 1000 500 0 2004 2005 2006 2007 2008 GETINGE 2009-03
Slide 17: Maturity of debts
Maturity of debts Lender/Facility 2009 2010 2011 2012 2013 2014 2015 USA Private Placement 100 MUSD Nov 50 MUSD Nov Bridge Financing Datascope SEB 865 MUSD Mar Syndicated Credit Facility with 7 banks 332,5 MEUR Jun Syndicated Credit Facility with 9 banks 810 MEUR Apr Nordic Investment Bank 500 MSEK
Slide 18: Revised outlook 2009
BUSINESS AREA INFECTION CONTROL HEALTHCARE Revised outlook 2009 We expect organic revenue growth of 2 -3 % in 2009 We expect pre tax profit excluding integration cost related to Datascope acquisition to grow by approximately 25% GETINGE 2009-03
Slide 19: Questions & Answers
Questions & Answers GETINGE 2009-03